Anebulo Pharmaceuticals, Inc. (ANEB) intrinsic value & 10-year financials
Anebulo Pharmaceuticals, Inc. (ANEB) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.31
- Market cap
- $10.5M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -127.4%
- Free cash flow (FY2025)
- —
ANEB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$8.5M | -$0.25 | — | — | -109.7% |
| FY2024 | — | -$8.2M | -$0.32 | — | — | -113.8% |
| FY2023 | — | -$11.7M | $0.47 | — | — | -91.4% |
| FY2022 | — | -$6.8M | $0.29 | — | — | -37.4% |
| FY2021 | — | -$30.3M | — | — | — | -284.9% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Anebulo Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Anebulo Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -71.0% ROIC.
Anebulo Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Anebulo Pharmaceuticals, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.